{"uri":"/api/stitches/v1/1452718.simple","count":13,"data":[{"inchikey":"LKJPYSCBVHEWIU-UHFFFAOYSA-N","charge":"0","treeView":["CHEBI_26878","CHEBI_83575","CHEBI_18379","CHEBI_29347","CHEBI_35850","CHEBI_83565"],"inchi":"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)","hasExactSynonym":["N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide"],"smiles":"C=1(C(=CC=C(C1)NC(C(CS(C=2C=CC(=CC2)F)(=O)=O)(O)C)=O)C#N)C(F)(F)F","mass":"430.370","label":"N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide","type":["Class"],"inSubset":["IUPAC"],"uri":"http://purl.obolibrary.org/obo/CHEBI_144093","_hasDbXref":["IUPAC"],"IAO_0000115":"A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.","hasOBONamespace":"chebi_ontology","notation":"CHEBI:144093","formula":"C18H14F4N2O4S","id":"CHEBI:144093","monoisotopicmass":"430.06104"},{"inchikey":"LKJPYSCBVHEWIU-KRWDZBQOSA-N","charge":"0","treeView":["CHEBI_144093"],"inchi":"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1","hasExactSynonym":["(2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide"],"smiles":"C=1(C(=CC=C(C1)NC([C@](CS(C=2C=CC(=CC2)F)(=O)=O)(O)C)=O)C#N)C(F)(F)F","hasRelatedSynonym":["(-)-bicalutamide","(R)-(-)bicalutamide","(R)-Casodex"],"mass":"430.370","label":["(R)-bicalutamide"],"type":["Class"],"inSubset":["ChEBI","ChemIDplus","IUPAC"],"uri":"http://purl.obolibrary.org/obo/CHEBI_39589","is_enantiomer_of":["CHEBI_144094"],"RO_0000087":["CHEBI_35610","CHEBI_35497"],"_hasDbXref":["PMID:27848066","PMID:16847400","PMID:24397920","PMID:23288837","PMID:26442831","ChEBI","ChemIDplus","IUPAC"],"hasDbXref":["PDBeChem:198","DrugBank:DB02932","CAS:113299-40-4"],"IAO_0000115":"A N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide that is the (R)-enantiomer of bicalutamide.","CAS":"113299-40-4","hasOBONamespace":"chebi_ontology","notation":"CHEBI:39589","formula":"C18H14F4N2O4S","id":"CHEBI:39589","monoisotopicmass":"430.06104"},{"iupac_name":"N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide","gene_name":["CYP3A4","CYP2C9","CYP2C19","CYP2D6","AR"],"inchikey":"LKJPYSCBVHEWIU-UHFFFAOYSA-N","smiles":"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F","biospecimen":["Blood","Urine"],"description":["Bicalutamide is only found in individuals that have used or taken this drug. It is an oral non-steroidal anti-androgen for prostate cancer. It binds to the androgen receptor.Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.","belongs to the class of organic compounds known as trifluoromethylbenzenes. These are organofluorine compounds that contain a benzene ring substituted with one or more trifluoromethyl groups."],"alternative_parent":["Alkyl fluorides","Anilides","Aryl fluorides","Benzenesulfonyl compounds","Benzonitriles","Carbonyl compounds","Fluorobenzenes","Hydrocarbon derivatives","N-arylamides","Nitriles","Organic oxides","Organofluorides","Organopnictogen compounds","Secondary carboxylic acid amides","Sulfones","Tertiary alcohols"],"accession":"HMDB15260","synonym":["Casodex","Zeneca brand OF bicalutamide","4'-Cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide","Astra brand OF bicalutamide","Cosudex","AstraZeneca brand OF bicalutamide"],"monisotopic_molecular_weight":430.061040456,"cellular":["Cytoplasm","Membrane"],"name":"Bicalutamide","cas_registry_number":"90357-06-5","id":"HMDB0015260","average_molecular_weight":430.373,"chemical_formula":"C18H14F4N2O4S","substituent":["Alcohol","Alkyl fluoride","Alkyl halide","Anilide","Aromatic homomonocyclic compound","Aryl fluoride","Aryl halide","Benzenesulfonyl group","Benzonitrile","Carbonitrile","Carbonyl group","Carboxamide group","Carboxylic acid derivative","Fluorobenzene","Halobenzene","Hydrocarbon derivative","N-arylamide","Nitrile","Organic nitrogen compound","Organic oxide","Organic oxygen compound","Organofluoride","Organohalogen compound","Organonitrogen compound","Organooxygen compound","Organopnictogen compound","Organosulfur compound","Secondary carboxylic acid amide","Sulfone","Sulfonyl","Tertiary alcohol","Trifluoromethylbenzene"]},{"broad_name":"bicalutamide","statusSource":"FDA Orange Book: bicalutamide","indicationSource":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c295b64-ec39-42ec-9f02-da5b42e775e1","smiles":"CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F","synonyms":"Calutide|Cosudex|ICI 176,334|Kalumid|casodex","targetSource":"https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_prod_list.xml_prod_list_card_pr?p_tsearch=A&p_id=130910|ChEMBL","target":"CYP2C19|AR","name":"bicalutamide","id":"bicalutamide","diseaseArea":"oncology","indication":"prostate cancer","moa":"androgen receptor antagonist","status":"Launched"},{"year_adr_report":"2001","smiles":"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F","generic_name":"Bicalutamide","reason_withdrawn":"Accelerated deaths","source":"https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0553-2","unii":"A0Z3NAU9DP","year_launched":"1995","year_withdrawn":"2003","id":"Bicalutamide","indication":"Prostate cancer","class":"Chemotherapeutic agent","moa":"Androgen receptor modulation","country_withdrawn":"Canada|UK","status":"Withdrawn"},{"CompoundDescriptionUri":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020498s025lbl.pdf"],"InVitroUseGuide":["Primary tumor cultures and PCa cell lines were treated with bicalutamide (0.1-10 uM) in the presence of dehydrotestosterone (10(-12) M) for 4 days. After bicalutamide treatment, no significant differences in the concentration that inhibits 50% were found among the different tumor cell lines (P = .081)."],"OriginatorUri":["http://adisinsight.springer.com/drugs/800000790"],"ModifiedDateTime":["2016-10-24"],"Cns":["CNS Non-penetrant"],"CompoundId":["1214"],"InVitroUri":["https://www.ncbi.nlm.nih.gov/pubmed/19285710"],"ChemblId":["CHEMBL409"],"Conditions":["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"],"ChemSpiderID":["2284"],"CnsComment":["The peripheral selectivity of bicalutamide has been shown to be due to poor penetration across the blood-brain barrier: tissue distribution studies with [3H]bicalutamide show that although it is concentrated in the organs of metabolism and secretion as well as in the prostate, the pituitary glands, and the seminal vesicles, levels in the hypothalamus and the central nervous system (CNS) are much lower than in blood."],"InVivoUseGuide":["one 50 mg tablet once daily (morning or evening), with or without food"],"Originator":["AstraZeneca"],"ConditionId":["2658"],"id":"BICALUTAMIDE","CnsUri":["https://www.ncbi.nlm.nih.gov/pubmed/8560673"],"Wikiurl":["https://en.wikipedia.org/wiki/Bicalutamide"],"Cid":["2375"],"COMPOUND_QCD":["false"],"Pmids":["24759320","23708653","23603339","23562765","23405127","23052036","22101440","21936524","21846139","21633166","21506597","21369450","21308717","21273442","21128595","21036700","20729295","20711410","20620411","20032058","19359544","19318562","19240160","19131511","19011039","18937151","18922931","18801408","18776922","18487222","18486176","18475288","18454446","18324785","18324645","17916567","17914592","17875733","17804755","17723170","17624924","17606915","17599054","17526768","17503469","17440980","17371283","17342749","17325745","17189428","17148459","17044078","16888681","16877366","16873375","16847815","16753443","16641147","16637073","16631469","16516039","16496412","16469299","16420057","16406940","16368782","16317058","16280763","16266977","16020486","16015592","15994348","15994225","15887248","15790403","15754350","15681525","15638997","15466214","15378487","15336702","15308689","15171712","15151957","15138554","14532843","12970580","12730620","12376534","12114440","12015321","11981028","11956172","11845989","11751618","11410519","11139396","11059779","10604720","10402478","10053169"],"CompoundSynonym":["(±)-4'-CYANO-Α,Α,Α-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE","BICALUTAMIDA","BICALUTAMIDE","BICALUTAMIDUM","CASODEX","ICI 176,334","ICI-176334","ICI176,334-1","PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (±)-","БИКАЛУТАМИД","بيكالوتاميد","比卡鲁胺","(2RS)-4'-CYANO-3-(4-FLUOROPHENYL-SULPHONYL)-2-HYDROXY-2-METHYL-3'-(TRIFLUOROMETHYL)PROPIONANILIDE","4'-CYANO-3-(4-FLUOROPHENYLSULFONYL)-2-HYDROXY-2-METHYL-3'-(TRIFLUOROMETHYL)PROPIONANILIDE","ASTRA BRAND OF BICALUTAMIDE","ASTRAZENECA BRAND OF BICALUTAMIDE","COSUDEX","ICI 176334","ICI-176,334","N-[4-CYANO-3-(TRIFLUOROMETHYL)PHENYL]-3-[(4-FLUOROBENZENE)SULFONYL]-2-HYDROXY-2-METHYLPROPANAMIDE","PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+-)-","ZENECA BRAND OF BICALUTAMIDE","RAFFOLUTIL","CHEMBL409","DB01128"],"CompoundName":["BICALUTAMIDE"],"CompoundSmiles":["CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F"],"InVivoUri":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020498s025lbl.pdf"],"StructureAlert":["true"],"Targets":["eyJQcmltYXJ5UG90ZW5jeVR5cGUiOiJVbmtub3duIiwiQ29uZGl0aW9uUmVmcyI6WyI0Njc2ODBiNDg3Il0sIlByaW1hcnlUYXJnZXRUeXBlIjoiQ2hFTUJMIiwiUHJpbWFyeVRhcmdldFVyaSI6Imh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzExOTMxODUxIiwiUHJpbWFyeVBvdGVuY3lVcmkiOiJVbmtub3duIiwiUHJpbWFyeVRhcmdldElkIjoiQ0hFTUJMMTg3MSIsIlRhcmdldFBoYXJtYWNvbG9neSI6IkFudGFnb25pc3QiLCJpZCI6ImEwNzc2MDQ3NGYiLCJQcmltYXJ5VGFyZ2V0TGFiZWwiOiJBbmRyb2dlbiBSZWNlcHRvciJ9"],"SMILES":"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F","TargetId":["56"],"BindingdbId":["18525"],"KeggId":["D00961"],"Unii":["A0Z3NAU9DP"],"Cas":["90357-06-5"],"Completed":["true"],"MOLFILE":"\n  Marvin  10082012450D          \n\n 29 30  0  0  0  0            999 V2000\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0000    0.0000    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n  1  2  1  0  0  0  0\n  2  3  1  0  0  0  0\n  2  4  1  0  0  0  0\n  4  5  1  0  0  0  0\n  5  6  2  0  0  0  0\n  5  7  2  0  0  0  0\n  5  8  1  0  0  0  0\n  8  9  2  3  0  0  0\n  9 10  1  0  0  0  0\n 10 11  2  3  0  0  0\n 11 12  1  0  0  0  0\n 11 13  1  0  0  0  0\n 13 14  2  3  0  0  0\n  8 14  1  0  0  0  0\n  2 15  1  0  0  0  0\n 15 16  2  0  0  0  0\n 15 17  1  0  0  0  0\n 17 18  1  0  0  0  0\n 18 19  2  3  0  0  0\n 19 20  1  0  0  0  0\n 20 21  2  3  0  0  0\n 21 22  1  0  0  0  0\n 22 23  3  0  0  0  0\n 21 24  1  0  0  0  0\n 24 25  2  3  0  0  0\n 18 25  1  0  0  0  0\n 24 26  1  0  0  0  0\n 26 27  1  0  0  0  0\n 26 28  1  0  0  0  0\n 26 29  1  0  0  0  0\nM  END\n","DrugbankId":["DB01128"],"InVivoUseRoute":["Oral"],"Iupac":["N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide"],"CompoundPatent":["JP4397691B2","JP2011528275A","JP2006265244A","JP2005060302A"],"CompoundDescription":["Bicalutamide (brand name Casodex) is an oral non-steroidal anti-androgen for prostate cancer. It is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels."]},{"Synonyms":["4'-Cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide","Astrazeneca brand of bicalutamide","Cosudex","Propanamide, n-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-","Casodex","Bicalutamidum","Ici-176334","Astra brand of bicalutamide","Ici 176334","Bicalutamide","(2Rs)-4'-cyano-3-(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide","Zeneca brand of bicalutamide","Ici-176,334","N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide"],"CompoundCID":["2375","441405","56069"],"CompoundMOA":["Androgen Antagonists","Antineoplastic Agents","Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue."],"REFS":["Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|MeSH (Medical Subject Headings File)||--Systematic Name--","Bicalutamide|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|HSDB (Hazardous Substances Data Bank)||--Name of Substance--","Bicalutamide|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|USPDDN (United States Pharmacopeia Dictionary of Drug Names)|USAN:INN:BAN|--Name of Substance--","Bicalutamide|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|Drugs@FDA (FDA Drug Database)||--Synonyms--","Casodex|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|Drugs@FDA (FDA Drug Database)||--Synonyms--","ICI 176334|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|MeSH (Medical Subject Headings File)||--Synonyms--","UNII-A0Z3NAU9DP|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|FDA SRS (FDA Substance Registration System)||--Synonyms--","90357-06-5|http://chem.sis.nlm.nih.gov/chemidplus/jsp/common/ChemFullDisplay.jsp?calledFrom=lite&chemid=0090357065|ChemIDPlus||--CAS Registry Number--","ClinicalTrials.gov||NCGC||","FDA DailyMed||NCGC||","NPC screening|NCGC00167977|NCGC||","Approved drugs||NCGC||","Human approved drugs||NCGC||","FDA approved||NCGC||","NPC informatics|NPC-7233587~Bosche Scientific, LLC:B4676~InterBioScreen Ltd.:STOCK6S-47735~NIH Center for Chemical Genomics:NCTR-231~Sequoia Research Product LTD:SRP02002b~Sigma - ALDRICH:Lopac-B9061|NCGC||","FDA human approved||NCGC||","HTS amenable drugs||NCGC||HTS amenable drugs","DrugBank v3.0|DB01128|NCGC||","QC spectra||NCGC||","90357-06-5|BICALUTAMIDE|KEGG||","90357-06-5|BICALUTAMIDE|Tariff||","90357-06-5|Bicalutamide|FDA maximum daily dose||","90357-06-5|Bicalutamide|Japan||","BICALUTAMIDE|CASODEX TAB 50MG|Canada||","BICALUTAMIDE|BICALUTAMIDE|KEGG||","Bicalutamide|BICALUTAMIDE|KEGG||","Bicalutamide|Bicalutamide|UK NHS||","BICALUTAMIDE|BICALUTAMIDE|Tariff||","Bicalutamide|Bicalutamide|FDA maximum daily dose||","BICALUTAMIDE|BICALUTAMIDE|FDA orange book||","BICALUTAMIDE|CASODEX|FDA orange book||","BICALUTAMIDE|CASODEX|FDA drugs@FDA||","BICALUTAMIDE|BICALUTAMIDE|FDA drugs@FDA||","Bicalutamide|Bicalutamide|Japan||","BICALUTAMIDE|BICALUTAMIDE|FDA NDC||","90357-06-5|bicalutamidum|INN2||"],"CURATIONS":["trung|NCGC|trung@jhu.edu|http://tripod.nih.gov|1307818930747","CompoundDisplay!","C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F!","C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F!","!","Pending!","||||1306911866941","Name!","null!","Bicalutamide!","!","Pending!","CompoundDisplay!","C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F!","C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F!","!","Pending!"],"CompoundIndication":["Antineoplastic","For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer."],"Wikipedia":["http://en.wikipedia.org/wiki/Bicalutamide"],"DATASET":["Canada","ClinicalTrials.gov","FDA DailyMed","NPC screening","Approved drugs","FDA maximum daily dose","FDA orange book","Community curation","Human approved drugs","FDA approved","INN","Tariff","KEGG","FDA NDC","FDA drugs@FDA","NPC informatics","UK NHS","FDA human approved","HTS amenable drugs","DrugBank v3.0","QC spectra","Japan"],"SMILES":"C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F","CompoundSpectra":["http://tripod.nih.gov/npc/spectra/NCGC00167487.png"],"CompoundUNII":["A0Z3NAU9DP"],"CAS":["90357-06-5"],"CLINICALTRIALS":["NCT00421694","NCT00418080","NCT00846976","NCT00551044","NCT01044706"],"MOLFILE":"Bicalutamide\n  Marvin  10082013112D          \n\n 29 30  0  0  0  0            999 V2000\n   -2.2136    0.4308    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.9217    0.0225    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -1.4871    0.0300    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.2286    1.2473    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.9217   -0.8053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -3.5846    0.4457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -1.4871   -0.8053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -1.5769    1.2360    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.2286    1.8991    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.9590    1.2360    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.1987   -1.2210    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -4.3861    0.8653    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   -0.8353   -1.2210    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   -0.0562   -0.7379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.6517   -1.1986    0.0000 C   0  0  1  0  0  0  0  0  0  0  0  0\n   -0.0412    0.0525    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    1.0113   -0.7379    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    1.1762   -1.8354    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.1348   -1.8354    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    1.9290   -0.7492    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    2.4422   -0.0974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.6941   -0.8316    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    2.2073   -1.4009    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    3.2849   -0.0974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.0377    0.6068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6895    0.6068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.4422    1.3260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.2587    1.3260    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.8505    2.0527    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n  1  2  2  0  0  0  0\n  1  3  1  0  0  0  0\n  1  4  1  0  0  0  0\n  2  5  1  0  0  0  0\n  2  6  1  0  0  0  0\n  3  7  2  0  0  0  0\n  4  8  1  0  0  0  0\n  4  9  1  0  0  0  0\n  4 10  1  0  0  0  0\n  5 11  2  0  0  0  0\n  6 12  3  0  0  0  0\n  7 13  1  0  0  0  0\n 13 14  1  0  0  0  0\n 14 15  1  0  0  0  0\n 14 16  2  0  0  0  0\n 15 17  1  0  0  0  0\n 15 18  1  1  0  0  0\n 15 19  1  6  0  0  0\n 17 20  1  0  0  0  0\n 20 21  1  0  0  0  0\n 20 22  2  0  0  0  0\n 20 23  2  0  0  0  0\n 21 24  2  0  0  0  0\n 21 25  1  0  0  0  0\n 24 26  1  0  0  0  0\n 25 27  2  0  0  0  0\n 26 28  2  0  0  0  0\n 28 29  1  0  0  0  0\n  7 11  1  0  0  0  0\n 27 28  1  0  0  0  0\nM  END\n","name":"Bicalutamide","CompoundDrugLabelRx":["51991-560;Bicalutamide;tablet, film coated;Bicalutamide;50 mg;A0Z3NAU9DP","0378-7017;Bicalutamide;tablet, film coated;Bicalutamide;50 mL;A0Z3NAU9DP","63672-0005;Bicalutamide;tablet, film coated;Bicalutamide;50 mg;A0Z3NAU9DP","51079-692;Bicalutamide;tablet, film coated;Bicalutamide;50 mg;A0Z3NAU9DP","54868-4503;Casodex;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP","0904-6019;Bicalutamide;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP","0093-0220;Bicalutamide;tablet, film coated;BICALUTAMIDE;50 mg;A0Z3NAU9DP","68084-374;Bicalutamide;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP","0781-5409;Bicalutamide;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP","65841-613;Bicalutamide;tablet, film coated;BICALUTAMIDE;50 mg;A0Z3NAU9DP","0310-0705;CASODEX;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP","67253-191;bicalutamide;tablet, film coated;bicalutamide;50 mg;A0Z3NAU9DP","16714-571;Bicalutamide;tablet, film coated;BICALUTAMIDE;50 mg;A0Z3NAU9DP","54868-6133;Bicalutamide;tablet, film coated;BICALUTAMIDE;50 mg;A0Z3NAU9DP","68382-224;Bicalutamide;tablet, film coated;BICALUTAMIDE;50 mg;A0Z3NAU9DP","41616-485;Bicalutamide;tablet;BICALUTAMIDE;50 mg;A0Z3NAU9DP"],"TARGETS":["Androgen receptor (ANDR_HUMAN)|Homo sapiens|~AR~DHTR~NR3C4|P10275|A2RUN2|B1AKD7|Q9UD95"],"id":"QPV","ID":["QPV"]},{"EVMPD":["SUB05817MIG"],"ActiveMoieties":["A0Z3NAU9DP"],"INN":["7021"],"WHO-ATC":["L02BB03","L02AE51"],"MESH":["C053541"],"uuid":["8f5c0a0d-71ce-49ae-92eb-b6685e0e0671"],"relationships":["ACTIVE MOIETY|A0Z3NAU9DP","ACTIVE ISOMER->PARENT|Z9DL98I0AF","INACTIVE ISOMER->PARENT|R8K39AN732","BASIS OF STRENGTH->SUBSTANCE|A0Z3NAU9DP","IMPURITY->PARENT|15LQ88H10F","IMPURITY->PARENT|R1DYX669ZK","IMPURITY->PARENT|ATU20DB5JB","IMPURITY->PARENT|L47D9XHC08","IMPURITY->PARENT|135IE10O4Y","TARGET->AGONIST|EJC4C3UYXH","TARGET->INHIBITOR|EJC4C3UYXH","BINDER->LIGAND|6D53G0FD0Z"],"WIKIPEDIA":["BICALUTAMIDE"],"MERCK INDEX":["M2474"],"NCI_THESAURUS":["C1599"],"ChEMBL":["CHEMBL409"],"id":"A0Z3NAU9DP","WHO-VATC":["QL02BB03"],"UNII":["A0Z3NAU9DP"],"Synonyms":["BICALUTAMIDE [VANDF]","BICALUTAMIDE [EP]","BICALUTAMIDE [WHO-DD]","BICALUTAMIDE [USP-RS]","BICALUTAMIDE [HSDB]","BICALUTAMIDE [MI]","BICALUTAMIDE [MART.]","BICALUTAMIDE [ORANGE BOOK]","BICALUTAMIDE [JAN]","BICALUTAMIDE [USP]","BICALUTAMIDE [INN]","BICALUTAMIDE [USAN]","(+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE"],"Codes":["ICI176,334-1","ICI-176334","ICI 176,334","NCIT:C1599","CAS:90357-06-5","MESH:C053541","CHEMBL409","CID:2375"],"LIVERTOX":["105"],"NDF-RT":["N0000000243","N0000175560"],"HSDB":["90357-06-5"],"SMILES":"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F","IUPHAR":["2863"],"CAS":["90357-06-5"],"DRUG BANK":["DB01128"],"References":["STN","USP DICTIONARY 2011","FDA_SRS","USP DICTIONARY 2010","USP Dictionary 2010","BICALUTAMIDE [VANDF]","BICALUTAMIDE [EP]","BICALUTAMIDE [WHO-DD]","BICALUTAMIDE [USP-RS]","BICALUTAMIDE [HSDB]","BICALUTAMIDE [MI]","BICALUTAMIDE [MART.]","BICALUTAMIDE [ORANGE BOOK]","BICALUTAMIDE [JAN]","BICALUTAMIDE [USP]","BICALUTAMIDE [INN]","BICALUTAMIDE [USAN]","SRS import [A0Z3NAU9DP]","BIOMED RES INT. 2017;2017:3572394. DOI: 10.1155/2017/3572394.","USP 35 BICALUTAMIDE MONOGRAPH","EP 7.5 BICALUTAMIDE MONOGRAPH","CLINICAL PHARMACOKINETICS,\\\\nNOVEMBER 2004, VOLUME 43, ISSUE 13, PP 855-878","CLINICAL PHARMACOKINETICS, NOVEMBER 2004, VOLUME 43, ISSUE 13, PP 855-878","SRS CODE IMPORT","NDF-RT","EP 7.5","CLINICAL TRIALS","WHO-DD","USP/NF","HSDB","MERCK INDEX","MARTINDALE 2011","ORANGE BOOK 2011","KEGG 2011","USP 33","INN 2010","WEBSITE","https://www.clinicalkey.com/pharmacology/monograph/67?sec=monphar"],"EPA CompTox":["90357-06-5"],"MOLFILE":"A0Z3NAU9DP\n  Marvin  10082011502D          \n\n 29 30  0  0  0  0            999 V2000\n    7.6431   -6.9197    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    6.9314   -8.1514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.9313   -7.3265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.2188   -7.4542    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.1092   -8.1544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6400   -8.1688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.7025   -8.8719    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    1.5861   -8.8748    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    7.2276   -6.1964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.4111   -8.8777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.2333   -8.8806    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.3635   -6.5014    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.0585   -7.6402    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    4.4708   -8.1660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.8804   -8.8777    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.6996   -7.4455    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    2.8004   -6.7396    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    6.9343   -8.9707    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    7.6344   -5.4847    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.3997   -6.1935    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6487   -9.5981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.4737   -9.5981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.4056   -4.7643    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    7.7564   -8.1457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.9901   -5.4818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    7.2218   -4.7671    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.0017   -4.0380    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6284   -6.7367    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    2.3966   -7.4484    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n  3  1  1  0  0  0  0\n  4  6  1  0  0  0  0\n  5  2  1  0  0  0  0\n  6 14  2  0  0  0  0\n  7  5  1  0  0  0  0\n  8 10  3  0  0  0  0\n  9  1  1  0  0  0  0\n 10 11  1  0  0  0  0\n 11 21  2  0  0  0  0\n 12  1  2  0  0  0  0\n 13  1  2  0  0  0  0\n 14 15  1  0  0  0  0\n 15  7  1  0  0  0  0\n 16  5  2  0  0  0  0\n 17  4  1  0  0  0  0\n  2 18  1  0  0  0  0\n 19  9  2  0  0  0  0\n 20  9  1  0  0  0  0\n 21 22  1  0  0  0  0\n 22 15  2  0  0  0  0\n 23 25  1  0  0  0  0\n  2 24  1  0  0  0  0\n 25 20  2  0  0  0  0\n 26 19  1  0  0  0  0\n 27 23  1  0  0  0  0\n 23 26  2  0  0  0  0\n 11  6  1  0  0  0  0\n  4 28  1  0  0  0  0\n  2  3  1  0  0  0  0\n  4 29  1  0  0  0  0\nM  END\n","name":"A0Z3NAU9DP","Class":["chemical"],"RXCUI":["83008"]},{"Synonyms":["R-BICALUTAMIDE","BICALUTAMIDE, (-)-","(-)-BICALUTAMIDE","(R)-BICALUTAMIDE","BICALUTAMIDE, (R)-"],"Codes":["AZD-1907","CAS:113299-40-4","CID:56069"],"SMILES":"C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F","uuid":["5ba78c34-dea4-4606-aa62-1cd60670472e"],"CAS":["113299-40-4"],"References":["STN","https://patents.google.com/patent/US20080161404A1/en","SRS import [Z9DL98I0AF]","CLINICAL PHARMACOKINETICS, NOVEMBER 2004, VOLUME 43, ISSUE 13, PP 855-878","SRS CODE IMPORT","STN (SCIFINDER)","FDA_SRS"],"name":"Z9DL98I0AF","MOLFILE":"Z9DL98I0AF\n  Marvin  10082011522D          \n\n 29 30  0  0  1  0            999 V2000\n    7.6646   -0.4384    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    8.0795   -1.1515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.9045   -1.1515    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.3195   -1.8616    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    7.6695   -1.8674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   10.0374   -2.8757    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.9095   -2.5775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.0845   -2.5775    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.3244   -3.2906    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    9.7393   -4.0037    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.6142   -3.7055    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.4391   -4.5305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.6142   -4.5305    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    7.3742   -3.8203    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.6142   -5.3555    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    7.7892   -4.5305    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    7.3791   -5.2521    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    5.3093   -3.1129    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    6.5542   -5.2521    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.1392   -4.5419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.1441   -5.9709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.3142   -4.5419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.8992   -3.8288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.4843   -3.1158    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    5.3191   -5.9709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.9042   -5.2578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.0742   -3.8288    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0\n    4.0792   -5.2578    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.2542   -5.2578    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n  1  2  1  0  0  0  0\n  2  3  2  0  0  0  0\n  3  4  1  0  0  0  0\n  2  5  1  0  0  0  0\n  4  7  2  0  0  0  0\n  5  8  2  0  0  0  0\n  8  7  1  0  0  0  0\n  7  9  1  0  0  0  0\n  6  9  2  0  0  0  0\n 10  9  2  0  0  0  0\n 11  9  1  0  0  0  0\n 13 12  1  1  0  0  0\n 13 11  1  0  0  0  0\n 13 15  1  0  0  0  0\n 14 16  2  0  0  0  0\n 16 13  1  0  0  0  0\n 17 16  1  0  0  0  0\n 19 17  1  0  0  0  0\n 20 19  1  0  0  0  0\n 21 19  2  0  0  0  0\n 22 20  2  0  0  0  0\n 23 18  1  0  0  0  0\n 23 22  1  0  0  0  0\n 24 23  1  0  0  0  0\n 25 21  1  0  0  0  0\n 26 22  1  0  0  0  0\n 26 25  2  0  0  0  0\n 23 27  1  0  0  0  0\n 28 26  1  0  0  0  0\n 29 28  3  0  0  0  0\nM  END\n","Class":["chemical"],"id":"Z9DL98I0AF","PreferredName":["BICALUTAMIDE, (R)-"],"UNII":["Z9DL98I0AF"]},{"InChIKey":"LKJPYSCBVHEWIU-KRWDZBQOSA-N","drugbank-id-others":["EXPT00064"],"synonyms":["(-)-Bicalutamide"],"xml":"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","name":"(R)-Bicalutamide","groups":["experimental"],"description":"transport","SMILES":"C[C@](O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F","id":"DB02932","drugbank-id":"DB02932","unii":"Z9DL98I0AF"},{"charge":"0","treeView":["CHEBI_60911"],"hasExactSynonym":["rac-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide","Bicalutamide"],"hasRelatedSynonym":["Calutide","bicalutamidum","Bicusan","ICI 176334","bicalutamida","Cosudex","Bicatlon","Calumid","Bicadex","Bypro","Ormandyl","Bicamide","Calutol","Binabic","(+-)-bicalutamide","ICI 176,334","bicalutamide","racemic bicalutamide","(RS)-4'-cyano-alpha',alpha',alpha',-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide","Casodex","Bical","Bicalox","ICI-176334","(RS)-bicalutamide","Kalumid"],"mass":"430.370","label":["bicalutamide"],"type":["Class"],"inSubset":["LINCS","DrugBank","WHO_MedNet","ChEBI","Wikipedia","ChemIDplus","IUPAC"],"uri":"http://purl.obolibrary.org/obo/CHEBI_3090","hasAlternativeId":"CHEBI:91617","RO_0000087":["CHEBI_35497","CHEBI_78298","CHEBI_35703","CHEBI_35610"],"_hasDbXref":["PMID:31099426","PMID:18062751","PMID:12421104","PMID:23527766","PMID:12017896","PMID:30784326","PMID:17313204","PMID:11915584","PMID:12015321","PMID:15509184","PMID:19194583","PMID:12959312","ChEBI","WHO_MedNet","DrugBank","LINCS","ChemIDplus","IUPAC"],"hasDbXref":["Beilstein:5364666","KEGG:C08160","HMDB:HMDB0015260","Patent:EP100172","Drug_Central:367","Patent:US4636505","LINCS:LSM-1437","KEGG:D00961","DrugBank:DB01128","CAS:90357-06-5","Reaxys:5364666"],"IAO_0000115":"A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.","CAS":"90357-06-5","hasOBONamespace":"chebi_ontology","notation":"CHEBI:3090","formula":"C18H14F4N2O4S","id":"CHEBI:3090","monoisotopicmass":"430.06104","BFO_0000051":["CHEBI_39589","CHEBI_144094"]},{"Chemical Name":"Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl- (racemic mixture)","CAS":"90357-06-0","Raw Materials":"2-Mercaptopyridine-N-oxide\n4-Amino-2-trifluoromethylbenzonitrile\n4-Fluorbenzenethiol\nBromal\nCitramalic acid\nDioxolanone\nThionyl chloride","References":"James K.D., Ekwuribe N.N.; Tetrahedron, V. 58, Is. 29, pp.5905-5908, (2002)\nTucker H.; US Patent No. 4,636,505; Jan. 13, 1987; Assigned: Imperial\nChemical Industries PLC (London, GB2)","Common Name":"Bicalutamide","UNII PT":"Bicalutamide","id":"A0Z3NAU9DP","Drug Products":"eyJQcm9kdWN0IjoiQmljYWx1dGFtaWRlIiwiQ29tcGFueSI6IkFzdHJhWmVuZWNhIn0=\neyJQcm9kdWN0IjoiQmlwcm9zdGEiLCJDb21wYW55IjoiQ3l0b21lZCAoQSBkaXYuIG9mIn0=\neyJQcm9kdWN0IjoiQ2FsdXRpZGUtNTAifQ==\neyJQcm9kdWN0IjoiQ2Fzb2RleCJ9\neyJQcm9kdWN0IjoiQ29zdWRleCJ9\neyJQcm9kdWN0IjoiUmFmZm9sdXRpbCJ9","UNII":"A0Z3NAU9DP","Drug Substance":"Bicalutamide","Therapeutic Function":"Antitumor"},{"mechanism-of-action":"Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.","synonyms":["Bicalutamida","Bicalutamide","Bicalutamidum"],"pharmacodynamics":"Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.","groups":["approved"],"description":"transport","SMILES":"CC(O)(CS(=O)(=O)C1=CC=C(F)C=C1)C(=O)NC1=CC(=C(C=C1)C#N)C(F)(F)F","half-life":"5.9 days","unii":"A0Z3NAU9DP","InChIKey":"LKJPYSCBVHEWIU-UHFFFAOYSA-N","drugbank-id-others":["APRD00042","DB06284"],"xml":"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","name":"Bicalutamide","clearance":"* Apparent oral cl=0.32 L/h [Normal Males]","metabolism":"Bicalutamide undergoes stereo specific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.","id":"DB01128","indication":"For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.","drugbank-id":"DB01128"}]}